MainReads
← Details
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial
David P Carbone, Tudor-Eliade Ciuleanu, Michael Schenker, Manuel Cobo, Stéphanie Bordenave, Oscar Juan-Vidal, Juliana Menezes, Niels Reinmuth, Eduardo Richardet, Ying Cheng, Hideaki Mizutani, Enriqueta Felip, Bogdan Zurawski, Aurelia Alexandru, Luis Paz-Ares, Shun Lu, Thomas John, Xiaoqing Zhang, Javed Mahmood, Nan Hu, Tuli De, Irene Santi, John R Penrod, Yong Yuan, Adam Lee, Martin Reck
/
-
Loading document from repository...
Unable to Display Document
The online reader was unable to display this document directly. This may occur if the repository host is temporarily unreachable, or if security restrictions (CORS) prevent embedded viewing.